FAST NEWS: InnoCare Pharma Slumps after Flagship Drug Included on China’s National List
The latest: InnoCare Pharma Ltd. (9969.HK) said late Friday that its Bruton’s tyrosine kinase inhibitor Orelabrutinib, used to treat lymphoma and autoimmune diseases, has been included on the National Reimbursement…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- A McDonald’s Valuation Downsize, and New Medical Plan Additions
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
